HBV is hyperendemic to southern Africa and parts of Asia, but licensed antivirals have little effect on limiting life-threatening complications of the infection. Although RNA interference (RNAi)-based gene silencing has shown therapeutic potential, difficulties with delivery of anti-HBV RNAi effectors remain an obstacle to their clinical use. To address concerns about the transient nature of transgene expression and toxicity resulting from immunostimulation by recombinant adenovirus vectors (Ads), utility of RNAi-activating anti-HBV helper-dependent (HD) Ads were assessed in this study.
Methods
Following intravenous administration of 5x109 unmodified or pegylated HD Ad infectious particles to HBV transgenic mice, HBV viral loads and serum HBV surface antigen levels were monitored for 12 weeks. Immunostimulation of HD Ads was assessed by measuring inflammatory cytokines, hepatic function and immune response to the co-delivered LacZ reporter gene.
Results
Unmodified and pegylated HD Ads transduced 80–90% of hepatocytes and expressed short hairpin RNAs (shRNAs) were processed to generate intended HBV-targeting guides. Markers of HBV replication were decreased by approximately 95% and silencing was sustained for 8 weeks. Unmodified HD Ads induced release of proinflammatory cytokines and there was evidence of an adaptive immune response to β-galactosidase. However the HD Ad-induced innate immune response was minimal in preparations that were enriched with infectious particles.
Conclusions
HD Ads have potential utility for delivery of therapeutic HBV-silencing sequences and alterations of these vectors to attenuate their immune responses may further improve their efficacy.
ArbuthnotP., KewM.Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol2001; 82: 77–100.
3.
KeeffeE.B., DieterichD.T., HanS.H.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol2006; 4: 936–962.
ArbuthnotP.Harnessing RNA interference for the treatment of viral infections. Drug News Perspect2010; 23: 341–350.
6.
ChenY., ChengG., MahatoR.I.RNAi for treating hepatitis B viral infection. Pharm Res2008; 25: 72–86.
7.
IvacikD., ElyA., ArbuthnotP.Countering hepatitis B virus infection using RNAi: how far are we from the clinic?Rev Med Virol2011; 21: 383–396.
8.
McCaffreyA.P.RNA interference inhibitors of hepatitis B virus. Ann N Y Acad Sci2009; 1175: 15–23.
9.
CastanottoD., RossiJ.J.The promises and pitfalls of RNA-interference-based therapeutics. Nature2009; 457: 426–433.
10.
BrummelkampT.R., BernardsR., AgamiR.A system for stable expression of short interfering RNAs in mammalian cells. Science2002; 296: 550–553.
11.
LeeN.S., DohjimaT., BauerG.Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol2002; 20: 500–505.
12.
MiyagishiM., TairaK.U6 promoter driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol2002; 20: 497–500.
13.
PaulC.P., GoodP.D., WinerI., EngelkeD.R.Effective expression of small interfering RNA in human cells. Nat Biotechnol2002; 20: 505–508.
14.
MowaM.B., CrowtherC., ArbuthnotP.Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Expert Opin Drug Deliv2010; 7: 1373–1385.
15.
SchnellM.A., ZhangY., TazelaarJ.Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther2001; 3: 708–722.
GuidottiL.G., ChisariF.V.Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol2001; 19: 65–91.
19.
CarmonaS., ElyA., CrowtherC.Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther2006; 13: 411–421.
20.
CrowtherC., ElyA., HornbyJ.Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther2008; 19: 1325–1331.
21.
UprichardS.L., BoydB., AlthageA., ChisariF V.Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci U S A2005; 102: 773–778.
22.
MowaM.B., CrowtherC., ElyA., ArbuthnotP.Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of antiviral primary micro RNA shuttles. Micro RNA2012; 1: 19–25.
23.
McCoyR.D., DavidsonB.L., RoesslerB.J.Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Hum Gene Ther1995; 6: 1553–1560.
24.
RaperS.E., YudkoffM., ChirmuleN.A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther2002; 13: 163–175.
25.
YeiS., MitterederN., WertS., WhitsettJ.A., WilmottR.W., TrapnellB.C.In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther1994; 5: 731–744.
26.
RauschhuberC., XuH., SalazarF.H., MarionP.L., EhrhardtA.Exploring gene-deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice. J Gene Med2008; 10: 878–889.
27.
MarionP.L., SalazarF.H., LiittschwagerK.A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus. In SchinaziR.F., SommadossiJ-P, RichC.M. (Editors). Frontiers in viral hepatitis. Amsterdam: Elsevier Science2003; pp. 197–202.
28.
HeT.C., ZhouS., da CostaL.T., YuJ., KinzlerK.W., VogelsteinB.A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A1998; 95: 2509–2514.
29.
PalmerD., NgP.Improved system for helper-dependent adenoviral vector production. Mol Ther2003; 8: 846–852.
30.
MokH., PalmerD.J., NgP., BarryM.A.Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther2005; 11: 66–79.
31.
WeinbergM.S., ElyA., BarichievyS.Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther2007; 15: 534–541.
32.
JiangH., WangZ., SerraD., FrankM.M., AmalfitanoA.Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther2004; 10: 1140–1142.
33.
HeL., HakimiJ., SalhaD., MironI., DunnP., RadvanyiL.A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. J Immunol Methods2005; 304: 43–59.
34.
ElyA., NaidooT., MufamadiS., CrowtherC., ArbuthnotP.Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther2008; 16: 1105–1112.
35.
JoossK., YangY., FisherK.J., WilsonJ.M.Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol1998; 72: 4212–4223.
36.
Brunetti-PierriN., ClarkeC., ManeV.Phenotypic correction of ornithine transcarbamylase deficiency using low dose helper-dependent adenoviral vectors. J Gene Med2008; 10: 890–896.
37.
Brunetti-PierriN., StapletonG.E., LawM.Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates. Mol Ther2009; 17: 327–333.
38.
ZaissA.K., MachadoH.B., HerschmanH.R.The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem2009; 108: 778–790.
39.
CotterM.J., MuruveD.A.The induction of inflammation by adenovirus vectors used for gene therapy. Front Biosci2005; 10: 1098–1105.
40.
LiuQ., ZaissA.K., ColarussoP.The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther2003; 14: 627–643.
41.
McCaffreyA.P., FawcettP., NakaiH.The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther2008; 16: 931–941.
MuruveD.A., CotterM.J., ZaissA.K.Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol2004; 78: 5966–5972.
44.
ArbuthnotP., LongshawV., NaidooT., WeinbergM.S.Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. J Viral Hepat2007; 14: 447–459.
Brunetti-PierriN., NgT., IannittiD.A.Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates. Hum Gene Ther2006; 17: 391–404.
47.
GrimmD., StreetzK.L., JoplingC.L.Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature2006; 441: 537–541.
48.
DanielssonA., ElgueG., NilssonB.M.An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood. Gene Ther2010; 17: 752–762.
49.
SchifferJ.T., AubertM., WeberN.D., MintzerE., StoneD., JeromeK.R.Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol2012; 86: 8920–8936.
50.
MoollaN., KewM., ArbuthnotP.Regulatory elements of hepatitis B virus transcription. J Viral Hepat2002; 9: 323–331.
